Table 2.

Risk of biochemical recurrence of prostate cancer in relation to phosphodiesterase type 5 inhibitor (PDE5i) exposure on multivariable conditional regression

	Odds ratio (95% confidence interval)
	Radical prostatectomy	Radiotherapy
PDE5i use
No	1.00 (reference)	1.00 (reference)
Yes	0.78 (0.59–1.03)	0.98 (0.49–1.97)
Married
No	1.00 (reference)	1.00 (reference)
Yes	0.79 (0.59–1.06)	2.10 (0.98–4.51)
Educational level
Low	1.00 (reference)	1.00 (reference)
Middle	0.98 (0.72–1.34)	0.80 (0.38–1.68)
High	1.08 (0.75–1.54)	1.09 (0.46–2.59)
Annual income (per quartile)	0.93 (0.82–1.06)	0.99 (0.71–1.39)
PSA (per 1 ng/ml)	1.14 (1.10–1.17)	1.08 (1.00–1.15)
Clinical T2 (reference T1)	2.08 (1.59–2.72)	1.41 (0.74–2.68)
Biopsy Gleason grade group	1.28 (1.11–1.46)	1.68 (1.30–2.18)
Proportion of positive biopsies
≤33%	1.00 (reference)	1.00 (reference)
>33%	1.46 (1.11–1.93)	0.99 (0.50–1.98)

PSA = prostate-specific antigen.